Top re­search ex­ecs from Te­va, Al­ler­gan re­cruit­ed to help lead Ax­o­vant out of the R&D waste­land

Roivant’s Vivek Ra­maswamy may have run in­to a nasty mess with the fail­ure of Ax­o­vant’s lead Alzheimer’s drug, but he can still re­cruit top tal­ent for his grow­ing or­ga­ni­za­tion.

Ex-Te­va R&D chief Michael Hay­den is com­ing on board as a se­nior sci­en­tif­ic ad­vis­er as well as head of sub­sidiary Ax­o­vant’s sci­en­tif­ic ad­vi­so­ry board. That marks a big step to open­ing his next chap­ter in bio­phar­ma af­ter get­ting blown up in the big Te­va re­or­ga­ni­za­tion that fol­lowed weak gener­ic rev­enue and a pal­try R&D game plan. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER